This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miron, T. Articles by Rabinkov, A. Search for Related Content PubMed PubMed Citation Articles by Miron, T. Articles by Rabinkov, A.

Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel

Requests for Reprints: Aharon Rabinkov, Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel. Phone: 972-8-9344340; Fax: 972-8-9468256. E-mail: bfrabin{at}wicc.weizmann.ac.il

Allicin (diallyl thiosulfinate), a highly active component in extracts of freshly crushed garlic, is the interaction product of non-protein amino acid alliin (S-allyl-L-cysteine sulfoxide) with the enzyme alliinase (alliin lyase; EC 4.4.1.4). Allicin was shown to be toxic in various mammalian cells in a dose-dependent manner in vitro. We made use of this cytotoxicity to develop a novel approach to cancer treatment, based on site-directed generation of allicin. Alliinase from garlic was chemically conjugated to a mAb directed against a specific tumor marker, ErbB2. After the mAb-alliinase conjugate was bound to target tumor cells, the substrate, alliin, was added. In the presence of alliin, tumor-localized alliinase produced allicin, which effectively killed N87 and CB2, both ErbB2-expressing cells in vitro, whereas 32D cells (a murine hematopoietic progenitor cell line, devoid of the ErbB2 receptors) were not affected. Moreover, using N87, a human tumor cell line xenograft in athymic nude mice, we demonstrated for the first time, a high antitumor activity of allicin that was produced in situ by the conjugate, on alliin administration in vivo, while at the same time other tissues were unharmed due to the inert nature of alliin and the high clearance rate of allicin. The effect of the treatment on tumor growth arrest became significant 2 weeks after its onset, and it continued to rise, reaching highly significant inhibition a week later. Ten days after the end of the treatment (day 18), tumor growth inhibition was still the same.

Key Words: Allicin • Alliinase • ADEPT • ErbB2 • Tumor growth

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Grant support: Levine Center and Yeda Co. at the Weizmann Institute of Science.

Received 8/ 5/03; revised 9/18/03; accepted 10/ 1/03.

This article has been cited by other articles:

				J. T. Pinto, B. F. Krasnikov, and A. J. L. Cooper Redox-Sensitive Proteins Are Potential Targets of Garlic-Derived Mercaptocysteine Derivatives J. Nutr., March 1, 2006; 136(3): 835S - 841S. [Abstract] [Full Text] [PDF]

				F. D. Arditti, A. Rabinkov, T. Miron, Y. Reisner, A. Berrebi, M. Wilchek, and D. Mirelman Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate Mol. Cancer Ther., February 1, 2005; 4(2): 325 - 332. [Abstract] [Full Text] [PDF]

				M. Wilchek My life with affinity Protein Sci., November 1, 2004; 13(11): 3066 - 3070. [Full Text] [PDF]